Groupe la Francaise Trims Stake in Boston Scientific Corporation $BSX

Groupe la Francaise cut its position in Boston Scientific Corporation (NYSE:BSX) by 88.6% in the second quarter, Holdings Channel reports. The firm owned 39,419 shares of the medical equipment provider’s stock after selling 307,482 shares during the period. Groupe la Francaise’s holdings in Boston Scientific were worth $1,679,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its position in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares during the last quarter. FWL Investment Management LLC purchased a new stake in Boston Scientific in the 2nd quarter valued at $26,000. Main Street Financial Solutions LLC raised its position in Boston Scientific by 35.3% in the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock valued at $812,000 after purchasing an additional 1,971 shares during the last quarter. Ieq Capital LLC boosted its stake in Boston Scientific by 97.0% during the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock worth $13,275,000 after purchasing an additional 60,860 shares during the period. Finally, HUB Investment Partners LLC boosted its stake in Boston Scientific by 56.2% during the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock worth $763,000 after purchasing an additional 2,556 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on BSX. Zacks Research lowered shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. Wall Street Zen downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, August 2nd. The Goldman Sachs Group set a $71.00 price target on Boston Scientific in a report on Thursday, May 28th. Needham & Company LLC dropped their price target on Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research report on Wednesday, July 8th. Finally, Raymond James Financial reaffirmed an “outperform” rating and set a $57.00 price objective on shares of Boston Scientific in a research note on Thursday, July 30th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $71.62.

Insider Activity at Boston Scientific

In related news, Director David C. Habiger bought 2,100 shares of the firm’s stock in a transaction on Wednesday, August 5th. The shares were bought at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the transaction, the director owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Michael F. Mahoney purchased 186,240 shares of the stock in a transaction dated Monday, August 3rd. The shares were bought at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the purchase, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 194,522 shares of company stock worth $9,385,210 over the last three months. 0.34% of the stock is currently owned by corporate insiders.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific said manufacturing and shipping operations are recovering, which could limit the disruption and support a gradual rebound in revenue and profitability. The company also expects multiple product launches and cost savings to aid longer-term growth. Boston Scientific Says It Won’t Meet 2026 Guidance After Cyberattack
• Neutral Sentiment: The company has not provided a replacement forecast, leaving investors without clear visibility into the size or duration of the financial impact. Management’s ability to restore systems and normalize shipments will be key near-term catalysts. Boston Scientific says cyberattack likely to hurt 2026 sales, profit
• Negative Sentiment: Boston Scientific said it is unlikely to meet its 2026 net-sales growth and earnings-per-share guidance ranges, including its previously issued third-quarter and full-year outlook. That reversal is driving the stock’s decline because it signals weaker near-term revenue, profit and cash-flow expectations. Boston Scientific Won’t Meet Guidance Due to Cyberattack
• Negative Sentiment: The incident adds operational and execution risk to pressure already affecting parts of the portfolio, including WATCHMAN and electrophysiology products. Investors are now likely to focus on the timing of the recovery, the ultimate size of the earnings shortfall and whether customer orders can be fully restored. Boston Scientific’s 2026 Growth Outlook Weakens

Boston Scientific Trading Down 5.9%

NYSE BSX opened at $45.00 on Wednesday. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $65.22 billion, a P/E ratio of 18.22, a P/E/G ratio of 1.10 and a beta of 0.57. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The firm has a 50-day moving average price of $47.04 and a 200 day moving average price of $55.18.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter in the previous year, the company earned $0.75 EPS. The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts expect that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific announced that its board has approved a share repurchase program on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s management believes its shares are undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company’s products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.